Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference
Ocugen, Inc. (OCGN)
Company Research
Source: GlobeNewswire
MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its head of Research and Development, Arun Upadhyay, PhD, will present pre-clinical data demonstrating how the company’s second modifier gene therapy candidate, OCU410, could potentially be an effective therapeutic for Dry Age-related Macular Degeneration (Dry AMD). The presentation, at the 2nd Annual Dry AMD Therapeutic Development conference, will showcase how the use of a specific nuclear hormone receptor called RORA presents a unique opportunity to treat people with Dry AMD. Dry AMD accounts for 85 to 90 percent of all cases of age-related macular degeneration, which is estimated to be about 196 million people globally. RORA plays a central role in many physiological activities, including lipid metaboli
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors Can Join the Class Action Lawsuit!Accesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGNAccesswire
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmAccesswire
- ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenPR Newswire
- ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGNPR Newswire
OCGN
Earnings
- 11/9/23 - Beat
OCGN
Sec Filings
- 4/18/24 - Form S-3
- 4/18/24 - Form S-8
- 4/17/24 - Form 4
- OCGN's page on the SEC website